Liver Pathophys Flashcards
psychometric testing
sensitive for detecting impairment in mild HE
lead to the identificaltion of minimal HE
Wilson’s Disease
inadequate copper excretion and failure of copper to ener circulation as ceruloplasmin –> multiorgan Cu accumulation
ATP7B genetic defect with Autosomal recessive (in hepatocytes, transfers Cu into secretory pway by binding it to ceruloplasmin and facilitates biliary excretion)
Basal ganglia degernation - depression, parkinsons
Ceruloplasmin decreases, Cirrhosis, Corneal deposits (KF rings) Copper accumulation, Caricnoma (hepatocellular)
Dementia

interface hepatitis - AIH
mononuclear infiltrate invading through the limiting plate
lab tests to assess liver disease progression
fibrosis, cirrhosis, seerity
proteins involved in EC matrix modeling and other blood tests
not gret yet
Hepatopulmonary Syndrome
present when this triad:
1. Liver disease
2. impaired oxygenation
3. intrapulmonary vascular dilations (IPVDS)
decreased GFR
decreased renal perfusion
absence of identifiable cause
Labs in Wilson’s
low serum ceruloplasmin (if not bound to copper, short half life and degraded quickly)
low serum Cu (serum Cu actually means Cu bound to ceruloplasmin which is low)
high urinary Cu (unbound Cu excreted by kidneys)
High heaptic Cu (biopsy)
portal htn in portal vein?
hypercoag
trauma
malignancy
direct bilirubin
conjugated Bb is water soluble and can be measred “directly” using colorimetric methods - dye in serum, measure normally
Normal value is very low. It is about .1-.3mg/dL because the liver is putting out that conjugated bilirubin. So it is not circulating.
unconjugated hyperbilirubinemia
defective uptake and conjugation
inhereted (defects in UDPGT)
liver immaturing (physiologic jaundice of newborns Bb = 4-5)
Natural history of NAFLD
20% progress to NASH
11% progress to cirrhosis (possible decompensation)
both can progress to HCC
increased mortality
80% have fatty liver
min progression to cirrhosis
increased CV, diabetes risk

Hepatitis C labs
mostly becomes chronic
develop anti-HCV but it’s not protective
can have ab and may be chronically infected
•You can measure in the acute phase as well as the chronic phase the virus. The antibodies doesn’t tell you that the patient isn’t immune any longer. It is just evidence that they have been affected as some point. It is not like the surface antibodies in HBV that tells you the patient is immune. Most of these people don’t recover

treatment of HDV
treat HBV
if clear HBV will clear HDV
interferon is only therapy against HDV!
HCV genotype
6!
1a/1b in US
imp for treatment
labs in liver failure
increased Bb (T and D)
hypoalbuminemia
increased PT (INR)
increased ammonia –> encephalopathy
NAFLD
30% of americans have NAFLD
dyslipidemia
obesity
T2D
comprises “fatty liver” and NASH
fat droplets in the hepatocytes
PSC and IBD
80% have concimitent IBD
IBD patients have increased risk of PSC
more colitis = greater risk
must do colo to evaluated for IBD
Treatment for herediatry hemochromatosis
goal is ferritin <50
phlebotomy is gold standard - improes fatigue, liver enzymes, skin, varices
does not improve arthralgias
may imrpove diabetes or cardiac
weekly for 2 years then maintenence every 3 months for life
screening of relatives
prescott nomogram
risk of toxicity for acetaminophen
primary sclerosing cholangitis
chronic progressive cholestatic disease of both intra and extra hepatic ducts
inflammation and fibrosis of bile ducts - stricutres and dilation
80% have concomitant IBD (UC more)
progressive risk of cholangicarcinoma, HCC, gallbladder cancer
only treatment is liver transplant

conjugated bilirubin
direct - water soluble
•Conjugated bilirubin: the bilirubin has already been glucuronized and can be excreted into the bile
Course of herediatry hemocrhomatosis

Autoimmune sclerosing cholangitis
AIH = PSC
like PSC
transient elastography
measures liver tissue elasticity by measuring speed of vbrations through parenchma
detect advanced fibrosis

Clinical manifestations of herediary hemochromatosis
- biochemical - steady increase in Fe stores from birth, clinically quiescent
- parenchymal accumulation - elevated ferritin, clinically quiescent
- end organ toxicity/failure - 30-50 years, cirrhosis and HCC, CCA, arrithymias and CHF, diabetes


































